In Hyderabad, India, 84% of IT workers have non-alcoholic fatty liver
HQ Team April 24, 2025: More than 84% of 345 information technology workers surveyed in an Indian city suffer from non-alcoholic fatty liver.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 24, 2025: More than 84% of 345 information technology workers surveyed in an Indian city suffer from non-alcoholic fatty liver.
HQ Team April 23, 2025: A UN agency, the Stop TB Partnership’s Global Drug Facility (GDF), cut the price of pretomanid, a key.
HQ Team April 23: Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms.
HQ Team April 23, 2025: Displacement caused by an internal conflict between the government and armed militants, weather extremes, and funding cuts is.
April 22, 2025: In a world increasingly run by algorithms, it’s not just playlists or grocery orders—your feelings might be next. From digital.
HQ Team April 18, 2025: Generic drugs made in India, which account for 93% of such medicines made from emerging countries, are linked.
HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.
HQ Team April 17, 2025: Stem cell therapies, which replace dead cells in the brain, can stop movement problems, rigidity and tremors in.
HQ Team April 17, 2025: Escalating hostilities and limited access to medical supplies are exacerbating an already dire humanitarian crisis in Gaza depriving.
HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.